Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis-Reference-Cited by-同舟云学术

Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis

Published:2007-05 Issue:5 Volume:2 Page:397-401
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Pujol Jean-Louis,Paul Sofia,Chouaki Nadia,Peterson Patrick,Moore Patti,Berry Donald A.,Salzberg Marc

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000;Shibuya;BMC Cancer,2002

2. Management of metastatic non-small cell lung cancer in 2006: innovations and unique clinical scenarios;Martins,2006

3. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003;Pfister;J Clin Oncol,2004

4. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

5. Second line chemotherapy for NSCLC: establishing a gold standard;Fossella;Lung Cancer,2002

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of CIMAvax-EGF administered in community polyclinics;Frontiers in Oncology;2024-01-18

2. Efficacy of Pharmaceutical Care for Patients with Lung Cancer Undergoing Chemotherapy: A Randomized Controlled Trial;J BIOL REG HOMEOS AG;2023

3. Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma;Asia-Pacific Journal of Clinical Oncology;2022-04-20

4. Chemotherapy for Lung Cancer;Medical Radiology;2022

5. Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid;Lung Cancer;2021-02